lenalidomide has been researched along with Dermatitis Medicamentosa in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (12.50) | 29.6817 |
| 2010's | 20 (83.33) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Eikenberg, JD; Grider, DJ; Patel, RT; Phillips, MA; Quan, EY | 1 |
| Bosly, A; Bouabdallah, R; Briere, J; Caballero, D; Cabeçadas, J; Casasnovas, RO; Catalano, J; Choufi, B; Cohen, AM; Coiffier, B; Corront, B; Fruchart, C; Gaulard, P; Gomes da Silva, M; Gonzalez, H; Greil, R; Grosicka, A; Haioun, C; Lazarovici, J; Lopez-Guillermo, A; Morschhauser, F; Oberic, L; Perrot, A; Salles, G; Sebban, C; Thieblemont, C; Tilly, H; Trotman, J; van Eygen, K; Van Hoof, A | 1 |
| Chan, TSY; Kwong, YL; Mak, V | 1 |
| Avivi, I; Berg, D; Einsele, H; Esseltine, DL; Gupta, N; Hájek, R; Hari, P; Kumar, S; Liberati, AM; Lin, J; Lonial, S; Ludwig, H; Masszi, T; Mateos, MV; Minnema, MC; Moreau, P; Richardson, PG; Romeril, K; Shustik, C; Spencer, A | 1 |
| Bladé, JS; Boudin, L; de Jauréguiberry, JP; Patient, M; Roméo, E | 1 |
| Catakovic, K; Egle, A; Gassner, FJ; Geisberger, R; Girschikofsky, M; Greil, R; Hartmann, TN; Lang, A; Melchardt, T; Petzer, A; Pleyer, L; Steurer, M; Thaler, J; Voskova, D; Weiss, L; Zaborsky, N | 1 |
| Asada, H; Miyagawa, F; Miyao, M; Nishikawa, M; Ogawa, K; Yamamoto, S | 1 |
| Kaiser, T; Metze, M; Petros, S; Pfrepper, C; Pierer, M; Poenisch, W | 1 |
| Bahlis, NJ; Bailey, K; Duggan, P; Jimenez-Zepeda, VH; McCulloch, S; Neri, P; Tay, J; Yau, P | 1 |
| Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A | 1 |
| Berardi Vilei, S; Berthod, G; Caspar, C; Eckhardt, K; Fischer, N; Hitz, F; Mey, U; Pabst, T; Zucca, E | 1 |
| Anagnostopoulos, N; Anargyrou, K; Briasoulis, E; Giannakoulas, N; Hatzimichael, E; Karras, G; Katodritou, E; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Lalagianni, C; Maniatis, A; Matsouka, P; Michali, E; Papageorgiou, G; Spanoudakis, E; Symeonidis, A; Terpos, E; Tsakiridou, A; Tsionos, K; Vadikolia, C; Zikos, P | 1 |
| Escudero-Vilaplana, V; Osorio Prendes, S; Sanjurjo Sáez, M | 1 |
| Kardaun, SH; Kuiper, EM | 1 |
| Eve, HE; Rule, SA | 1 |
| Frosch, P; Grape, J | 1 |
| Bruijnen, CP; Cornelisse, PB; Cornelissen, JJ; Emmelot, M; Huisman, C; Huls, G; Janssen, JJ; Kersten, MJ; Kneppers, E; Lokhorst, HM; Meijer, E; Minnema, MC; Mutis, T; Sonneveld, P; van der Holt, B; Zweegman, S | 1 |
| Demierre, MF; Goldberg, LJ; Kuohung, V | 1 |
| Allegra, A; Alonci, A; Cannavò, A; D'Angelo, A; Musolino, C; Penna, G; Petrungaro, A; Romeo, G; Russo, S | 1 |
| Caravita, T; De Bellis, A; de Fabritiis, P; Dentamaro, T; Morino, L; Musto, P; Perrotti, A; Siniscalchi, A; Tendas, A | 1 |
| Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A | 1 |
| Badros, A; Deng, A; Gaspari, A; Harvey, V; Junkins-Hopkins, JM; Oghilikhan, M; Samuels, A; Sina, B; Strobel, D | 1 |
| Davis, MD; Dispenzieri, A; Rajkumar, SV; Sviggum, HP | 1 |
| Tariman, JD | 1 |
1 review(s) available for lenalidomide and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma.
Topics: Anorexia; Antineoplastic Agents; Apoptosis; Constipation; Diarrhea; Drug Eruptions; Drug Monitoring; Dyspnea; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Nurse's Role; Nursing Assessment; Oncology Nursing; Thalidomide; Thrombocytopenia; Thromboembolism; Treatment Failure | 2007 |
6 trial(s) available for lenalidomide and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Eruptions; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Placebos; Prednisone; Rituximab; Survival Rate; Thalidomide; Vincristine | 2017 |
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Eruptions; Follow-Up Studies; Glycine; Hematologic Diseases; Humans; Lenalidomide; Leukocyte Count; Male; Middle Aged; Multiple Myeloma; Nausea; Peripheral Nervous System Diseases; Platelet Count; Thalidomide; Vomiting | 2017 |
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Consolidation Chemotherapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Hematologic Diseases; Humans; Immunity, Cellular; Immunologic Memory; Immunotherapy; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Remission Induction; Rituximab; T-Lymphocyte Subsets; Thalidomide; Treatment Outcome; Vidarabine | 2018 |
Sorafenib in patients with refractory or recurrent multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Eruptions; Drug Resistance, Neoplasm; Fatigue; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha; Lenalidomide; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Niacinamide; Pain; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Recurrence; Remission Induction; Salvage Therapy; Sorafenib; Thalidomide; Treatment Outcome | 2013 |
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Comorbidity; Dose-Response Relationship, Drug; Drug Eruptions; Fatigue; Female; Heart Diseases; Hematologic Diseases; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Nitrogen Mustard Compounds; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Drug Eruptions; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Lymphocyte Count; Male; Melphalan; Middle Aged; Multiple Myeloma; Mycophenolic Acid; Prospective Studies; Remission Induction; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 2011 |
17 other study(ies) available for lenalidomide and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Lenalidomide-induced symmetrical drug-related intertriginous and flexural exanthema.
Topics: Drug Eruptions; Erythema; Exanthema; Humans; Lenalidomide; Skin | 2023 |
Complete radiologic and molecular response of HIV-negative primary effusion lymphoma with short-course lenalidomide.
Topics: Aged, 80 and over; DNA, Viral; Drug Eruptions; Drug Monitoring; Eosinophilia; Epstein-Barr Virus Infections; Gastrointestinal Stromal Tumors; Herpesvirus 4, Human; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Primary Effusion; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Radiography, Thoracic; Treatment Outcome; Tumor Burden | 2017 |
[Lenalidomide desensitization in a patient with 5q- syndrome].
Topics: Aged; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Desensitization, Immunologic; Drug Administration Schedule; Drug Eruptions; Female; Humans; Immunologic Factors; Lenalidomide | 2017 |
Predisposition to multi-drug hypersensitivity after administration of mogamulizumab.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Diuretics; Drug Eruptions; Esomeprazole; Factor Xa Inhibitors; Fatal Outcome; Female; Furosemide; Humans; Immunologic Factors; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Middle Aged; Proton Pump Inhibitors; Pyridines; Thiazoles; Trimethoprim, Sulfamethoxazole Drug Combination | 2018 |
Inhibitor eradication in refractory acquired hemophilia with lenalidomide.
Topics: Autoantibodies; Autoimmune Diseases; Drug Eruptions; Drug Substitution; Factor VIII; Hemophilia A; Hemorrhage; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Paraplegia; Spinal Cord | 2019 |
Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center.
Topics: Aged; Aged, 80 and over; Cancer Care Facilities; Desensitization, Immunologic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Exanthema; Female; Humans; Hypersensitivity, Delayed; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Outpatient Clinics, Hospital; Skin; Time Factors; Treatment Outcome | 2019 |
"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Drug Eruptions; Drug Evaluation; Female; Follow-Up Studies; Gastrointestinal Diseases; Greece; Hematologic Diseases; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Proportional Hazards Models; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Thalidomide; Treatment Outcome; Venous Thrombosis | 2014 |
[Suspected itchy rash secondary to lenalidomide].
Topics: Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Drug Eruptions; Exanthema; Female; Humans; Lenalidomide; Prednisone; Thalidomide | 2014 |
Late onset perforating folliculitis induced by lenalidomide: a case report.
Topics: Drug Eruptions; Folliculitis; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Thalidomide | 2015 |
Lenalidomide-induced tumour flare reaction in mantle cell lymphoma.
Topics: Antineoplastic Agents; Drug Eruptions; Fatal Outcome; Female; Humans; Lenalidomide; Leukocytosis; Lymphoma, Mantle-Cell; Male; Splenomegaly; Thalidomide | 2010 |
[Papular drug eruption along the lines of Blaschko caused by lenalidomide].
Topics: Antineoplastic Agents; Diagnosis, Differential; Drug Eruptions; Humans; Leg Dermatoses; Lenalidomide; Male; Middle Aged; Patch Tests; Plasmacytoma; Skin Diseases, Papulosquamous; Thalidomide | 2011 |
Lenalidomide-induced purpuric eruption: a new adverse cutaneous reaction.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Drug Eruptions; Humans; Lenalidomide; Male; Purpura; Thalidomide | 2011 |
Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Dexamethasone; Drug Eruptions; Female; HLA-A Antigens; HLA-B Antigens; HLA-C Antigens; HLA-DQ beta-Chains; HLA-DRB1 Chains; Humans; Italy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prednisolone; Severity of Illness Index; Thalidomide; White People | 2012 |
Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Eruptions; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Stevens-Johnson Syndrome; Thalidomide | 2012 |
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Benzoates; Chelating Agents; Deferasirox; Drug Eruptions; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematinics; Humans; Iron Overload; Kidney Diseases; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide; Treatment Outcome; Triazoles | 2012 |
Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Biopsy; Diagnosis, Differential; Drug Eruptions; Etanercept; Female; Follow-Up Studies; Humans; Immunoglobulin G; Infliximab; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Skin; Thalidomide; Tumor Necrosis Factor-alpha | 2006 |
Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.
Topics: Amyloidosis; Anti-Inflammatory Agents; Clinical Trials as Topic; Dexamethasone; Drug Eruptions; Drug Therapy, Combination; Humans; Lenalidomide; Medical Records; Minnesota; Multiple Myeloma; Prevalence; Retrospective Studies; Severity of Illness Index; Thalidomide | 2006 |